Comparison of the inhibitory effect of ketoconazole, voriconazole, fluconazole, and itraconazole on the pharmacokinetics of bosentan and its corresponding active metabolite hydroxy bosentan in rats
- 3 July 2019
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 50 (3) , 280-287
Abstract
1. This study aimed to investigate the inhibitory effect of azole antifungal agents, including ketoconazole, voriconazole, fluconazole, and itraconazole, on the pharmacokinetics of bosentan (BOS) and its active metabolite hydroxy bosentan (OHBOS) in Sprague–Dawley (SD) rats. 2. A total of 25 healthy male SD rats were divided into five groups and treated with various azole antifungal agents by gavage, followed by a single dose of BOS after 30 min. 3. The study found that ketoconazole led to a significant increase (5.1-fold) in the AUC(0-t) of BOS, associated with a 5.8-fold elevation in the Cmax, which was greater than that for fluconazole (2.6- and 2.9-fold) and voriconazole (1.1- and 1.7-fold). Accordingly, the Vz/F and CLz/F of BOS reduced by 89.2% and 83.7%, respectively, on administering ketoconazole concomitantly. However, fluconazole caused a decrease in Vz/F and CLz/F by 77.4% and 72.2%, respectively, compared with voriconazole that exhibited a decrease in CLz/F by 51.7% with a negligible change in Vz/F. Also, obvious differences were observed in the pharmacokinetic parameters of OHBOS between the control and treated groups. 4. Collectively, treatment with ketoconazole resulted in a prominent inhibitory effect on the metabolism of BOS, followed by treatment with fluconazole, voriconazole, and itraconazole. Therefore, these details of animal studies may help draw more attention to the safety of BOS while combining it with ketoconazole, voriconazole, fluconazole, or itraconazole clinically.Keywords
Funding Information
- Zhejiang Natural Science Foundation (LY16H180008)
- Wenzhou Science and Technology Plan Project (Y20150082)
This publication has 34 references indexed in Scilit:
- Clinical Pharmacokinetics and Drug‐Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial HypertensionThe Journal of Clinical Pharmacology, 2012
- Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitorCancer Chemotherapy and Pharmacology, 2011
- Results of European post-marketing surveillance of bosentan in pulmonary hypertensionEuropean Respiratory Journal, 2007
- Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor AntagonistClinical Pharmacokinetics, 2004
- Single‐ and multiple‐dose pharmacokinetics of bosentan and its interaction with ketoconazoleBritish Journal of Clinical Pharmacology, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Pharmacokinetic Aspects of Treating Infections in the Intensive Care UnitClinical Pharmacokinetics, 2001
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 1999
- Pharmacokinetics of the Newer BenzodiazepinesClinical Pharmacokinetics, 1989